Diabetes
Conditions
Keywords
lifestyle intervention, artificial intelligence
Brief summary
The goal of this clinical trial is to learn about the application and effectiveness evaluation of artificial intelligence (AI) in lifestyle management of diabetic patients in community.
Detailed description
To determine the effectiveness of lifestyle intervention through AI on diabetic patients, whether it can improve blood sugar/ blood pressure/ body weight/ blood lipid control in people with type 1 or type 2 diabetes? Then find related risk factors. Participants will complete the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result, while the control group received routine lifestyle guidance. All included patients would fill in the patient's medication information according to the information content of the machine reading card, and follow up whether the medication is adjusted. The patient was included in the diabetes management we-chat group, followed up for 3 months /6 months according to the visit plan. The experimental group filled in the lifestyle assessment scale again, and personalized lifestyle intervention programs were provided according to the survey results, while the control group received routine follow-up and lifestyle guidance. Researchers will compare the two groups to see if the control of blood glucose, blood pressure, blood lipids and BMI of the experimental group after 6 months of AI-based lifestyle intervention was better than the control group.
Interventions
BEHAVIORALpersonalized lifestyle intervention by AI
The experimental group completed the basic information, diet structure, use of dietary supplements, living habits, and exercise according to the AI scale (AI scale can be entered through we-chat mini program search), and provided personalized lifestyle intervention plan according to the survey result.
Sponsors
Chongqing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Well informed of the procedures of this trial and informed consent is obtained * 18-80 years old, gender is not limited * Diagnosed diabetes (according to WHO1999 diagnostic criteria) * Well compliance
Exclusion criteria
* Pregnant or lactating * Poor blood glucose control (HbA1c\>11%) * A history of malignant tumor * Abnormal liver or renal function \[defined as alanine aminotransferase (ALT)\>2.5 times higher than normal range, or eGFR\<30 mL/min per 1.73 m2\] * Poor blood pressure control \[systolic blood pressure (SBP)\>180mmHg, or diastolic blood pressure (DBP)\>110mmHg * With severe heart disease, cardiac function worse than grade II, anemia (Hb\<9.0g/d1) * Blood routine test indicates that the white blood cell count (WBC) \<3\*109/L * Body Mass Index (BMI)\<18.5 or ≥35kg/m2 * Drug or alcohol abuse * Accompanying mental disorder who can't collaborate * Abnormal digestion and absorption function * Other endocrine diseases * Other chronic diseases needed long-term glucocorticoid treatment * With severe infection, immune dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of HbA1c | one year | Change of HbA1c from baseline to endpoint (1 year follow-up) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of systolic blood pressure | one year | Change of systolic blood pressure from baseline to endpoint |
| Change of diastolic blood pressure | one year | Reduction of diastolic blood pressure from baseline to endpoint |
| Change of LDL-c | one year | Change of LDL-c from baseline to endpoint |
Countries
China
Contacts
Primary ContactJinbo Hu, PhD
Backup ContactBing Kang, PhD
Outcome results
None listed